Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15646070rdf:typepubmed:Citationlld:pubmed
pubmed-article:15646070lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0042749lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0080194lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0017431lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0887947lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0302614lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C1706050lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C1516240lld:lifeskim
pubmed-article:15646070lifeskim:mentionsumls-concept:C0181090lld:lifeskim
pubmed-article:15646070pubmed:issue2 Suppl 1lld:pubmed
pubmed-article:15646070pubmed:dateCreated2005-1-13lld:pubmed
pubmed-article:15646070pubmed:abstractTextThe aim of this study was to evaluate outcome after a genotype guided change of therapy in 18 patients failing HAART. Patients were divided into two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and 6 failing patients (without immune recovery). At month 12 after genotype change of therapy a significant difference in the decrease of HIV-RNA viral load between the two groups of patients was detected (mean -1.95 and +0.04 log HIV-RNA copies/ml, p=0.04). One year after the change of therapy, all but one patients experienced a decrease in the replication capacity of HIV strains. Particularly, the HIV replication capacity of HIV strains decreased from 52% (range 14-98%) to 15.2% (range 0.1-74.5%). The HIV strains of patients failing HAART showed a progressive impaired replication capacity. In patients failing HAART the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.lld:pubmed
pubmed-article:15646070pubmed:languageenglld:pubmed
pubmed-article:15646070pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15646070pubmed:citationSubsetIMlld:pubmed
pubmed-article:15646070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15646070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15646070pubmed:statusMEDLINElld:pubmed
pubmed-article:15646070pubmed:monthAprlld:pubmed
pubmed-article:15646070pubmed:issn1121-7138lld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:VulloVVlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:AndreoniMMlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:SarmatiLLlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:MontanoMMlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:DoseSSlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:D'EttorreGGlld:pubmed
pubmed-article:15646070pubmed:authorpubmed-author:BuonominiA...lld:pubmed
pubmed-article:15646070pubmed:issnTypePrintlld:pubmed
pubmed-article:15646070pubmed:volume27lld:pubmed
pubmed-article:15646070pubmed:ownerNLMlld:pubmed
pubmed-article:15646070pubmed:authorsCompleteYlld:pubmed
pubmed-article:15646070pubmed:pagination95-8lld:pubmed
pubmed-article:15646070pubmed:dateRevised2011-2-25lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:meshHeadingpubmed-meshheading:15646070...lld:pubmed
pubmed-article:15646070pubmed:year2004lld:pubmed
pubmed-article:15646070pubmed:articleTitleDiscordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.lld:pubmed
pubmed-article:15646070pubmed:affiliationDepartment of Public Health, University of Rome Tor Vergata, Rome.lld:pubmed
pubmed-article:15646070pubmed:publicationTypeJournal Articlelld:pubmed